A quick peek into the report
Table of Contents
1.1 Market Outlook
1.1.1 Definitions
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Market Size, 2024 – 2035, $Million
1.1.4 Key Findings
1.1.5 Market Growth Scenario
1.1.5.1 Realistic Scenario
1.1.5.2 Optimistic Scenario
1.1.5.3 Pessimistic Scenario
1.2 Industry Outlook
1.2.1 NGS: Market Overview and Ecosystem
1.2.2 Asia-Pacific and Middle East NGS: Overview
1.2.3 Key Trends and Emerging Application of NGS in Asia-Pacific and Middle East
1.2.4 Patent Analysis
1.2.5 Pricing Analysis
1.2.5.1 Instrument
1.2.5.2 Consumables
1.2.6 Supply Chain Analysis
1.2.6.1 Key Entities in Supply Chain
1.2.7 Regulatory Framework
1.2.7.1 Asia-Pacific
1.2.7.2 Middle East
1.2.8 Genome Projects
1.2.8.1 Asia-Pacific
1.2.8.1.1 China
1.2.8.1.2 Japan
1.2.8.1.3 India
1.2.8.1.4 South Korea
1.2.8.1.5 Singapore
1.2.8.1.6 Other Asian Countries
1.2.8.2 Middle East
1.2.8.2.1 UAE
1.2.8.2.2 Qatar
1.2.8.2.3 Saudi Arabia
1.2.8.2.4 Kuwait
1.2.8.2.5 Other Middle East Countries
1.3 Market Dynamics
1.3.1 Market Drivers
1.3.1.1 Impact Analysis
1.3.2 Market Restraints
1.3.2.1 Impact Analysis
1.3.3 Market Opportunities
2.1 Consumables
2.1.1 Library Preparation and Reagents
2.1.2 Sequencing Kits and Reagents
2.1.3 Others
2.2 Equipment
2.3 Services
2.3.1 Sequencing Services
2.3.2 Data Management Services
3.1 Sequencing
3.2 Pre-Sequencing
3.3 Data Analysis
4.1 Overview
4.1.1 Asia-Pacific
4.1.2 Middle East
4.2 Illumina, Inc. (Asia-Pacific and Middle East)
4.2.1 iSeq
4.2.2 MiniSeq
4.2.3 MiSeq
4.2.4 NextSeq
4.2.5 NovaSeq
4.3 Thermo Fisher Scientific, Inc. (Asia-Pacific and Middle East)
4.3.1 Ion PGM
4.3.2 Ion Genestudio S5
4.3.3 Ion Proton
4.3.4 Ion Genexus
4.4 Pacific Biosciences of California, Inc. (Asia-Pacific and Middle East)
4.4.1 Sequel II/IIe
4.5 Oxford Nanopore Technologies plc. (Asia-Pacific and Middle East)
4.5.1 MinION
4.5.2 GridION
4.5.3 PromethION
4.6 Other Companies (Asia-Pacific and Middle East)
5.1 Overview
5.1.1 Asia-Pacific
5.1.2 Middle East
5.2 High-Throughput
5.3 Medium-Throughput
5.4 Low-Throughput
6.1 Sequencing by Synthesis
6.2 Ion Torrent Semiconductor Sequencing
6.3 Single Molecule Real-time Sequencing
6.4 Nanopore Sequencing Technologies
6.5 Other Technologies
7.1 Clinical Diagnostics
7.1.1 Oncology
7.1.2 Infectious Diseases
7.1.3 Reproductive Genetics
7.1.4 Others
7.2 Translational Research
7.2.1 Clinical
7.2.2 Agricultural
7.2.3 Others
8.1 Pharmaceutical and Biotechnology Companies
8.2 Academic and Research Institution
8.3 Clinical Laboratories
8.4 Others
9.1 Market Overview
9.2 Market Sizing and Forecast
9.2.1 Japan
9.2.2 China
9.2.3 India
9.2.4 South Korea
9.2.5 Australia
9.2.6 Singapore
9.2.7 New Zealand
9.2.8 Rest of Asia-Pacific
10.1 Market Overview
10.2 Market Sizing and Forecast
10.2.1 UAE
10.2.2 KSA
10.2.3 Israel
10.2.4 Egypt
10.2.5 Rest-of-Middle East
11.1 Competitive Benchmarking
11.2 Competitive Landscape
11.2.1 Key Strategies and Developments by Company
11.2.1.1 Funding Activities
11.2.1.2 Mergers and Acquisitions
11.2.1.3 Regulatory Approvals
11.2.1.4 Partnerships, Collaborations, and Business Expansions
11.2.2 Market Share Analysis, 2024-2035
11.2.3 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by End User)
11.2.4 Growth Share Analysis for Asia-Pacific and Middle East NGS Market (by Throughput)
11.3 Company Profiles
11.3.1 BGI Group
11.3.1.1.1 Company Overview
11.3.1.1.2 Product Portfolio
11.3.1.1.3 Key Competitors
11.3.1.1.4 Target Customers
11.3.1.1.5 Analyst Perspective
11.3.2 Illumina, Inc.
11.3.2.1.1 Company Overview
11.3.2.1.2 Product Portfolio
11.3.2.1.3 Key Competitors
11.3.2.1.4 Target Customers
11.3.2.1.5 Analyst Perspective
11.3.3 Thermo Fisher Scientific, Inc.
11.3.3.1.1 Company Overview
11.3.3.1.2 Product Portfolio
11.3.3.1.3 Key Competitors
11.3.3.1.4 Target Customers
11.3.3.1.5 Analyst Perspective
11.3.4 Pacific Biosciences of California, Inc.
11.3.4.1.1 Company Overview
11.3.4.1.2 Product Portfolio
11.3.4.1.3 Key Competitors
11.3.4.1.4 Target Customers
11.3.4.1.5 Analyst Perspective
11.3.5 Oxford Nanopore Technologies plc
11.3.5.1.1 Company Overview
11.3.5.1.2 Product Portfolio
11.3.5.1.3 Key Competitors
11.3.5.1.4 Target Customers
11.3.5.1.5 Analyst Perspective
11.4 Emerging Companies (Asia-Pacific and Middle East)
Asia-Pacific and Middle East NGS Market Report Coverage
|
Asia-Pacific and Middle East NGS Market |
|||
|
Base Year |
2024 |
Market Size in 2025 |
$XX Million |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Million |
|
CAGR During Forecast Period |
17.89% |
||
Key Asia-Pacific and Middle East NGS Market Players and Competition Synopsis:
The Asia-Pacific an Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share.
• BGI Group
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Pacific Biosciences of California, Inc.
• Oxford Nanopore Technologies plc
How can this report add value to an organization?
Type: The Asia-Pacific and Middle East NGS market has been extensively segmented on the basis of various categories such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Growth/Marketing Strategy: Synergistic activities and product launches/approvals accounted for the maximum number of key developments, i.e., over 70% of the total developments in the global Asia-Pacific and Middle East NGS market.
Competitive Strategy: The Asia-Pacific and Middle East NGS market is highly consolidated, with around six key players accounting for a vast majority of the market share. Key players in the Asia-Pacific and Middle East NGS market analyzed and profiled in the study involve established and players that offer various kinds of NGS platforms, consumables, and services.
Asia-Pacific and Middle East NGS Market Industry OverviewÂ
The Asia-Pacific and Middle East Next-Generation Sequencing (NGS) market is experiencing significant growth, driven by rapid advancements in next-generation sequencing technologies, the rising prevalence of genetic disorders and cancer, and the expanding application of next-generation sequencing in precision medicine. Continuous innovations in next-generation sequencing platforms have enhanced efficiency, accuracy, and cost-effectiveness, making next-generation sequencing more accessible for both clinical diagnostics and research purposes. The increasing demand for next-generation sequencing in personalized medicine, particularly in oncology, reproductive health, and infectious disease diagnostics, is further fueling market expansion. Additionally, strong government initiatives, increased R&D investments, and strategic collaborations between biotech firms and healthcare providers are propelling the growth of next-generation sequencing in the region. Countries such as China, India, and Saudi Arabia are leading large-scale genomic projects to advance early disease detection and precision healthcare, further strengthening the Asia-Pacific and Middle East NGS market landscape.
Despite the strong growth potential of the next-generation sequencing market, several challenges persist. The high cost associated with next-generation sequencing platforms, consumables, and data analysis tools remains a major barrier, particularly in low-income regions. The shortage of skilled professionals proficient in bioinformatics and genomic data interpretation further hinders the widespread adoption of next-generation sequencing technologies. Moreover, concerns related to data privacy, security, and regulatory compliance create complexities in the implementation of next-generation sequencing across different countries. Additionally, variations in healthcare regulations and ethical concerns surrounding genomic data usage add to the market’s constraints, making the adoption of next-generation sequencing more challenging in certain regions. This factor is posing a challenge for the Asia-Pacific and Middle East NGS market.
Nevertheless, the next-generation sequencing market in the Asia-Pacific and Middle East regions presents significant opportunities for expansion. Emerging economies with rapidly improving healthcare infrastructure are increasingly investing in next-generation sequencing research and clinical applications. The integration of artificial intelligence (AI) and cloud-based bioinformatics is revolutionizing genomic data analysis, making next-generation sequencing more efficient and accessible. Furthermore, the growing use of next-generation sequencing in non-invasive prenatal testing (NIPT) and infectious disease research offers new growth avenues for market players. As governments and private sector companies continue investing in genomic research, precision medicine, and clinical applications, the next-generation sequencing market in Asia-Pacific and the Middle East is poised for substantial expansion in the coming years.
The Asia-Pacific and Middle East NGS market report highlights that the market was valued at $XX million in 2024 and is expected to reach $XX million by the end of 2035. The market is expected to grow at a CAGR of 17.89% during the forecast period from 2025 to 2035.
Impact of COVID-19
Next-generation sequencing (NGS)-based products play a vital role in disease research and diagnostics, particularly in cancer detection and treatment, where next-generation sequencing enables personalized and targeted therapies for patients. The next-generation sequencing market is primarily driven by manufacturers of next-generation sequencing instruments, kits, assays, and service providers offering gene panels and oncology-focused testing services using next-generation sequencing technology. However, the COVID-19 pandemic negatively impacted revenue growth in the next-generation sequencing market due to disruptions in supply chains and healthcare operations, affecting the availability of next-generation sequencing products and services.
Despite these challenges, the pandemic underscored the critical role of next-generation sequencing in public health management, particularly in sequencing the SARS-CoV-2 virus, tracking its mutations, and monitoring population health. For example, in October 2022, Kyrgyzstan initiated efforts to enhance its next-generation sequencing capabilities for SARS-CoV-2 surveillance. Industry leaders in next-generation sequencing anticipate a shift toward local manufacturing to reduce dependence on imports, as the pandemic exposed weaknesses in global supply chains. Consequently, several countries in the Asia-Pacific and Middle East regions are prioritizing domestic production of essential medical supplies and next-generation sequencing tools to ensure a more stable and resilient healthcare infrastructure, propelling the the overall Asia-Pacific and Middle East NGS market.
The growth of the next-generation sequencing market is fueled by the increasing adoption of next-generation sequencing in diverse research and diagnostic applications, the rising prevalence of non-communicable diseases, and continuous advancements in next-generation sequencing platforms that enhance efficiency, speed, and accuracy. As the demand for next-generation sequencing continues to rise, innovations in next-generation sequencing technology will further drive market expansion, positioning next-generation sequencing as a fundamental tool in modern genomics and precision medicine.
Market Segmentation:
Segmentation 1: by Offerings
• Consumables
• Equipment
• Services
The Asia-Pacific and Middle East NGS market (by offerings) is expected to be dominated by the consumables segment.
Segmentation 2: by Platform
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Pacific BioSciences of California, Inc.
• Oxford Nanopore Technologies plc.
• Other Companies
The Asia-Pacific and Middle East NGS market (by platform) is expected to be dominated by Illumina, Inc.
Segmentation 3: by Throughput
• High-Throughput
• Medium-Throughput
• Low-Throughput
The Asia-Pacific and Middle East NGS market (by throughput) is expected to be dominated by the high-throughput segment.
Segmentation 4: by Technology Type
• Sequencing by Synthesis
• In Torrent Semiconductor Sequencing
• Single Molecule Real-Time Sequencing
• Nanopore Sequencing Technology
• Other Technologies
The Asia-Pacific NGS market (by technology type) is expected to be dominated by the sequencing by synthesis segment.
Segmentation 5: by Application
• Clinical Diagnostics
• Translational Research
• Other Applications
The Asia-Pacific NGS market (by technology type) is expected to be dominated by the translational research segment.
Segmentation 6: by End User
• Academic and Research Institutes
• Clinical Laboratories
• Pharmaceutical and Biotechnology Companies
• Other End Users
The Asia-Pacific NGS market (by end user) is expected to be dominated by the academic and research insitutes segment.
Segmentation 7: by Country
• Asia-Pacific
o Japan
o India
o South Korea
o Australia
o Singapore
o New Zealand
o Rest-of-Asia-Pacific
• Middle East
o U.A.E.
o K.S.A.
o Egypt
o Israel
o Rest-of-Middle East
The Asia-Pacific NGS market (by country) is expected to be dominated by Japan and the Middle East NGS market (by country) is expected to be dominated by the U.A.E.
Recent Developments in the Asia-Pacific and Middle East NGS Market
• In October 2022, PacBio introduced Revio and Onso, two new sequencing systems. Revio is a long-read sequencing system capable of sequencing up to 1,300 human whole genomes annually, while Onso is a benchtop short-read DNA sequencing platform. These systems enhance the scalability of PacBio’s HiFi sequencing technology, supporting large-scale studies in human genetics, oncology, and agricultural genomics.
• In September 2022, Illumina, Inc. launched Illumina Complete Long-Reads (INFINITY) for whole-genome sequencing (WGS). This innovation provided a high-performance, fully integrated sequencing method, compatible with all NovaSeq systems, enabling the synthesis of thousands of long-read genomes per year.
• Also in September 2022, Illumina, Inc. unveiled the NovaSeq 6000 Dx, the first FDA-registered and CE-marked high-throughput in vitro diagnostic (IVD) sequencer. Designed for clinical applications, this platform ensures high compliance standards while delivering critical insights to improve patient care.
• In August 2022, Illumina, Inc. partnered with the Minderoo Foundation, investing $27.8 million to advance genetic research on marine ecosystems. This collaboration utilized Illumina's NextSeq 2000 sequencing system to analyze marine biodiversity and better understand oceanic life.
• In April 2022, Genomics England extended its partnership with a sequencing company to explore the therapeutic and scientific potential of comprehensive genomic analysis of cancer tumors using nanopore sequencing technology as part of an ongoing project.
• In March 2022, a sequencing company launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, a fully automated system capable of generating sequencing data within a single day, streamlining diagnostic processes.
• In January 2022, Pacific Biosciences of California, Inc. collaborated with Genomics England to further the 100,000 Genomes Project by leveraging long-read sequencing technology to detect genetic variants in cancer and rare disease cases. As part of this initiative, Genomics England re-sequenced biobank samples to identify additional genomic variations that short-read sequencing technologies might not effectively capture.
Demand - Drivers and Limitations
The following are the drivers for the Asia-Pacific and Middle East NGS market:
• Increasing Adoption of NGS in Various Research and Diagnostics Field
• Growing Prevalence of Non-Communicable Diseases is Boosting the Demand for NGS
• Advancement in the Performance of NGS Platforms
The market is expected to face some limitations as well due to the following challenges:
• Dearth of Skilled Professionals in Middle East Countries
• High Cost of Installation and Maintenance of the Equipment
• Reimbursement and Regulatory Policies of NGS
Asia-Pacific and Middle East NGS Market
Focus on Offering, Platform, Throughput, Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035